New drug trial targets tough ovarian cancers
NCT ID NCT07341100
Summary
This study tests an experimental drug called SKB264 in patients with recurrent ovarian cancer. It aims to see if the drug shrinks tumors and how another medication (clarithromycin) affects SKB264 levels in the body. About 20 participants will receive SKB264 alone after an initial interaction check.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN EPITHELIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.